Lung Cancer and Mesothelioma CPG Mini-Module – Key Principles of Immune Related Adverse Events (irAEs)
The SITC Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. To complement the advanced live webinar series, three on-demand, mini modules will assist learners in applying lessons learned on specific topics within the use of immunotherapy in their own practices and locate additional resources to continue their education.
In this mini module, Jyoti D. Patel, MD, of the Lurie Cancer Center, Northwestern University discusses the mechanisms and management of adverse events associated with immunotherapy for lung cancer and mesothelioma. Topics include the mechanisms and kinetics underlying irAEs, the importance of understanding patient baseline activities prior to immunotherapy, and the Common Terminology Criteria for Adverse Events (CTCAE). This mini-module concludes with a discussion between Dr. Patel and Sarah B. Goldberg, MD, MPH, of Yale Cancer Center, on the timing of initiating immune checkpoint blockade after chemoradiation for lung cancer.
Run Time: 15 Minutes 37 Seconds
Clinicians and advanced practice providers who treat cancer patients are the target audience, including community physicians, oncologists, emergency room physicians, disease specialists, registered nurses, nurse practitioners, pharmacists, physician assistants and radiologists.
SITC Online Education Disclaimer
A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.
The Quick Education Modules are part of the Cancer Immunotherapy Clinical Practice Guidelines Advanced Webinar Series supported, in part, by grants from Amgen and Merck & Co., Inc. (as of 9/20/2021).
The SITC Clinical Practice Guidelines are produced and funded solely by SITC. No outside funding is received for the development of the manuscripts.